ArticleJournal of bone oncology2026
LL-37 inhibits osteosarcoma progression by suppressing SQLE-mediated cholesterol synthesis via the PTEN/AKT/mTOR pathway.
Article in Journal of bone oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is an aggressive primary bone malignancy with poor prognosis for metastatic and recurrent cases, highlighting an urgent need for novel therapeutic strategies. The human cathelicidin peptide LL-37 exerts context-dependent anti-tumor effects, yet its functional role in OS remains largely undefined. This study aimed to explore the anti-OS activity and underlying mechanisms of LL-37.
methodsIn vitro experiments were performed using OS cell lines and normal human bone marrow mesenchymal stem cells (hBMSCs) to assess cell viability, clonogenic survival, migration, invasion, cell cycle distribution, cell death, and cholesterol metabolism. Transcriptomic profiling, siRNA-mediated knockdown, plasmid overexpression, and rescue experiments were conducted to validate key signaling pathways. The in vivo therapeutic efficacy of LL-37 was evaluated using a 143B cell xenograft model.
resultsLL-37 selectively inhibited the viability of OS cells with minimal toxicity to hBMSCs. It significantly suppressed clonogenic survival, migration, and invasion, induced S-phase cell cycle arrest, and triggered both mitochondrial apoptosis and caspase-1/GSDMD-dependent pyroptosis. Transcriptomic analysis identified cholesterol biosynthesis as a key pathway downregulated by LL-37, with the rate-limiting enzyme squalene epoxidase (SQLE) markedly reduced. Mechanistically, LL-37 upregulated the tumor suppressor PTEN, thereby inhibiting the AKT/mTOR pathway and suppressing SREBP2/SQLE-mediated cholesterol synthesis. Rescue experiments confirmed that SQLE inhibition was required for the pro-apoptotic effects of LL-37. In vivo, LL-37 dose-dependently inhibited the growth of OS xenografts with efficacy comparable to cisplatin, without causing obvious systemic toxicity.
conclusionLL-37 exerts anti-OS effects by targeting the PTEN/AKT/mTOR-SREBP2/SQLE axis to suppress cholesterol synthesis and induce dual cell death. It represents a promising and selective candidate, providing a theoretical basis for cholesterol metabolism-targeted therapy in osteosarcoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.